Multiple myeloma is one of the areas where CAR-T cell therapy has made the biggest mark — and where China's research is watched most closely. If you or a family member has relapsed or refractory myeloma, here's what's worth understanding.

How CAR-T targets myeloma

Most myeloma CAR-T therapies are built to recognize a protein called BCMA (B-cell maturation antigen), which sits on the surface of myeloma cells. The patient's own T-cells are engineered to lock onto BCMA, then infused back to seek out and destroy the cancer. Newer designs targeting additional proteins, including dual-target approaches, are an active area of research in China.

Why China's myeloma pipeline matters

China runs the largest number of CAR-T trials of any country, and myeloma is a major focus. The clearest proof of how far the science has come:

A China-origin myeloma CAR-T reached the FDA. Ciltacabtagene autoleucel was first tested in China (in the CARTIFAN-1 study) and later approved by the US FDA for relapsed or refractory multiple myeloma. It shows that myeloma CAR-T developed in China can meet the bar of Western regulators — though it doesn't guarantee any particular trial will accept you or work for you.

Who might consider a trial

CAR-T trials for myeloma generally recruit patients whose disease has relapsed or become refractory after earlier lines of therapy — for example, after proteasome inhibitors and immunomodulatory drugs. For patients who have run low on approved options at home, or who face very high costs, a trial can be a meaningful path to next-generation therapy.

Eligibility is specific and decided by each trial's investigators. Criteria often consider your prior treatments, organ function, and disease status — which is why a records review is the real starting point, not a general checklist.

What to keep in mind

CAR-T is intensive and carries real risks, including cytokine release syndrome and neurological effects, which is why it's given at specialized centers. Responses vary and myeloma can return. A trial abroad also means travel and a multi-week stay. None of this makes it the wrong choice — but it should be a considered one, made with your treating hematologist.

Finding a myeloma trial in China

You can browse CAR-T trials recruiting in China — many list myeloma among their conditions — or send your details below for a free eligibility review focused on your history.